oncologic emergencies and GI toxicity Flashcards

(35 cards)

1
Q

4 types of cancer induced nausea and vomiting

A

anticipatory
acute
delayed
breakthrough/refractory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

risk factors for CINV

A
  • female
  • younger
  • poor emetic control in previous cycles
  • Hx of motion sickness
  • Hx of morning sickness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ondansetron MoA

A

inhibits serotonin receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ondansetron adverse effects

A

headache
constipation
diarrhea
QT prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ondansetron phase use

A

acute

delayed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

aprepitant MoA

A

inhibit NK1 receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

apreptiant adverse effects

A

fatigue
dizziness
diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

apreptiant phase use

A

acute

delayed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

phenothiazine drugs

A

prochlorperazine

promethazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

phenothiazines MoA

A

inhibit D2 receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

phenothiazines adverse effects

A

CNS depression
anticholinergic
extrapyramidal symptoms
hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

benzamide drug

A

metoclopramide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

metoclopramide MoA

A

inhibit D2 and serotonin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

metoclopramide adverse effects

A

sedation
diarrhea
EPS
QT prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

metoclopramide phase use

A

breakthrough/refractory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

phenothiazine phase use

A

acute
delayed
breakthrough

17
Q

atypical antipsychotic for N/V

18
Q

olanzapine MoA

A

inhibit dopamine and serotonin

19
Q

olanzapine adverse effects

A

somnolence
dry mouth
dizziness
QT prolongation

20
Q

olanzapine phase use

A

acute
delayed
refractory

21
Q

corticosteroid of choice for NV

A

dexamethasone

22
Q

dexamethasone phase use

A

acute

delayed

23
Q

benzodiazepine of choice for NV

24
Q

lorazepam phase use

A

anticipatory

breakthrough

25
cannabinoids phase use
breakthrough/refractory
26
cannabinoids adverse effects
anticholinergic sedation appetite stimulation hallucinations
27
general prophylaxis treatment for high risk NV
5HT3 + dexameth + aprepitant +- olanzapine
28
general prophylaxis treatment for moderate risk NV
5HT3 + dexameth +- aprepitant
29
general prophylaxis treatment for low risk NV
5HT3 or steroid or phenothiazone
30
treatment for mucositis
- mouthwash and coating agents - analgesics - corticosteroids
31
treatment of diarrhea
- hydration - BRAT diet and clear liquids - loperamide, octreotide
32
treatment of constipation
- stop nonessential meds - increase fluids - any laxitive
33
signs and symptoms of hypercalcemia
- fatigue and altered mental status - AKI - NV, anorexia, PUD - short QT, ventricular arrhythmia
34
Risk factors for tumor lysis syndrome
- highly proliferative - malignancies - high treatment sensitivity - renal dysfunction
35
management of spinal cord compression
- dexamethasone 10-100 mg bolus, 4-8 q6h - spinal radiation - surgery - chemo - pain management